Tuberculosis (TB) remains one of the leading causes of mortality worldwide, driven largely by delayed diagnosis and the emergence of drug-resistant strains. In recent years, the development and validation of biomarkers for tuberculosis have become central to improving early detection, disease monitoring, and therapy efficacy. Whether in the context of latent TB infection (LTBI) or active pulmonary TB, identifying reliable and reproducible biomarkers is a top priority in both clinical and research settings.
![Recombinant Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (inhA)](https://cdn-s5.efdu.com/uplodes/biomarkers-for-tb-1788529664485-e9e5403c.png)